With the NHS under such exceptional pressure during the coronavirus crisis, it’s easy to overlook the fact that the UK’s Brexit transition period ends on December 31. Mark Dayan takes a closer look at how these two challenges for the health service might collide, and says there is a case to err on the side of caution.

US, European, Japanese and Chinese patients could get novel medicines ahead of patients in the UK after Brexit, the CEO of French pharma Ipsen has said in an interview.